Current management of hepatocellular carcinoma

doi:10.3748/wjg.v20.i30.10223

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 30

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6629)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-10) series.

Item

Count

PDF

544

WORD

258

HTML

3919

Figures (1-1)

165

Tables (1-10)

137

Sum=5023

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

792

Download

814

Sum=1606

Aug 14, 2014 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (47)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Aug 14, 2014; 20(30): 10223-10237
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10223

Table 10 Ongoing and reported randomized phase II-III trials in the treatment of advanced hepatocellular carcinoma

Treatment	Acronym	Treatment	Primary outcome
First line treatment	¹SEARCH	Erlotinib + Sorafenib vs Sorafenib	OS
	¹BRISK-FL	Brivanib vs Sorafenib	OS
	-	Linifanib vs Sorafenib	OS
Second line treatment	¹EVOLVE-1	Everolimus vs Placebo	OS
	¹BRISK	Brivanib vs Placebo	OS
	¹BRISK-APS	Brivanib vs Placebo	OS
	Toh et al[158] 2010	Linifanib	OS: 9.7 mo
Phase 2 trial (reported)	Hsu et al[159] 2010	Sorafenib + Tegafur/Uracil	OS: 7.4 mo
	Thomas et al[160] 2007	Erlotinib	OS: 6.25 mo
	Thomas et al[161] 2009	Erlotinib + Bevacizumab	OS: 15.7 mo
	Faivre et al[162] 2009	Sunitinib	OS: 8 mo

¹ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/. OS: Overall survival.

Citation: Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237
URL: https://www.wjgnet.com/1007-9327/full/v20/i30/10223.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i30.10223